Endocrine| Volume 169, ISSUE 5, P1131-1138, May 2021

Operative intervention for recurrence of adrenocortical carcinoma: A single-center experience

Published:December 03, 2020DOI:



      Adrenocortical carcinoma is a rare endocrine malignancy with a high recurrence rate. The aim of this study was to evaluate the role of surgery for patients with local or distant recurrent adrenocortical carcinoma and to attempt to identify prognostic features related to survival benefit in patients undergoing resection of recurrence.


      The data of 47 patients with recurrent adrenocortical carcinoma in West China Hospital, Sichuan, China, between 2009 and 2019 were retrospectively collected. These patients were divided into 2 groups according to whether resection of recurrence was performed. The correlation between overall survival after recurrence and reoperation was evaluated. Kaplan-Meier and univariate/multivariate Cox regression methods were used to identify any prognostic factors.


      Included in our study were 21 patients who underwent reoperation and 26 patients who underwent nonoperative treatments were. The operation group had a better median overall survival after recurrence than the nonoperation group (19 months versus 6.5 months; P = .007). In the operated group, disease-free interval >12 months (P = .002), complete resection of recurrent adrenocortical carcinoma (P = .041), and R0 resection of the primary tumor (P = .005) were associated with prolonged survival after recurrence.


      Reoperation plays an important role in the management of selected patients with recurrent adrenocortical carcinoma. Disease-free interval, preoperative evaluation for complete resection, and R0 resection of the primary tumor are important prognostic characteristics for the resection of recurrent adrenocortical carcinoma. The overall survival after recurrence was significantly improved for patients who had a disease-free interval >12 months, and initial R0 resection or complete resection of recurrent adrenocortical carcinoma is feasible.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fassnacht M.
        • Libé R.
        • Kroiss M.
        • Allolio B.
        Adrenocortical carcinoma: a clinician’s update.
        Nat Rev Endocrinol. 2011; 7: 323-335
        • Else T.
        • Kim A.C.
        • Sabolch A.
        • et al.
        Adrenocortical carcinoma.
        Endocr Rev. 2014; 35: 282-326
        • Wandoloski M.
        • Bussey K.J.
        • Demeure M.J.
        Adrenocortical cancer.
        Surg Clin North Am. 2009; 89: 1255-1267
        • Fassnacht M.
        • Dekkers O.M.
        • Else T.
        • et al.
        European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
        Eur J Endocrinol. 2018; 179: G1-G46
        • Libé R.
        • Borget I.
        • Ronchi C.L.
        • et al.
        Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.
        Ann Oncol. 2015; 26: 2119-2125
        • Postlewait L.M.
        • Ethun C.G.
        • Tran T.B.
        • et al.
        Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group.
        J Am Coll Surg. 2016; 222: 480-490
        • Kroiss M.
        • Quinkler M.
        • Lutz W.K.
        • Allolio B.
        • Fassnacht M.
        Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
        Clin Endocrinol (Oxf). 2011; 75: 585-591
        • Mir M.C.
        • Klink J.C.
        • Guillotreau J.
        • et al.
        Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience.
        Ann Surg Oncol. 2013; 20: 1456-1461
        • Tran T.B.
        • Liou D.
        • Menon V.G.
        • Nissen N.N.
        Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis.
        Am Surg. 2013; 79: 1115-1118
        • Freire D.S.
        • Siqueira S.A.
        • Zerbini M.C.
        • et al.
        Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
        Clin Endocrinol (Oxf). 2013; 79: 468-475
        • Bedrose S.
        • Daher M.
        • Altameemi L.
        • Habra M.A.
        Adjuvant therapy in adrenocortical carcinoma: Reflections and future directions.
        Cancers (Basel). 2020; 12: 508
        • Lo W.M.
        • Kariya C.M.
        • Hernandez J.M.
        Operative management of recurrent and metastatic adrenocortical carcinoma: A systematic review.
        Am Surg. 2019; 85: 23-28
        • Dy B.M.
        • Wise K.B.
        • Richards M.L.
        • et al.
        Operative intervention for recurrent adrenocortical cancer.
        Surgery. 2013; 154 (discussion 1299): 1292-1299
        • Simon G.
        • Pattou F.
        • Mirallié E.
        • et al.
        Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study.
        Surgery. 2017; 161: 249-256
        • Erdogan I.
        • Deutschbein T.
        • Jurowich C.
        • et al.
        The role of surgery in the management of recurrent adrenocortical carcinoma.
        J Clin Endocrinol Metab. 2013; 98: 181-191
        • Datrice N.M.
        • Langan R.C.
        • Ripley R.T.
        • et al.
        Operative management for recurrent and metastatic adrenocortical carcinoma.
        J Surg Oncol. 2012; 105: 709-713
        • Grubbs E.
        • Lee J.E.
        Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.
        Cancer. 2009; 115 (author reply 5848): 847
        • Gaujoux S.
        • Mihai R.
        • joint working group of ESES and ENSAT
        European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma.
        Br J Surg. 2017; 104: 358-376
        • Tran T.B.
        • Maithel S.K.
        • Pawlik T.M.
        • et al.
        Clinical score predicting long-term survival after repeat resection for recurrent adrenocortical carcinoma.
        J Am Coll Surg. 2016; 223: 794-803
        • Zhang F.
        • Zhang F.
        • Liu Z.
        • Wu K.
        • Zhu Y.
        • Lu Y.
        Prognostic role of Ki-67 in adrenocortical carcinoma after primary resection: a retrospective mono-institutional study.
        Adv Ther. 2019; 36: 2756-2768
        • Lo W.
        • Ayabe R.I.
        • Kariya C.M.
        • et al.
        Stage and disease-free interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma.
        J Surg Oncol. 2019; 121: 228-233
        • Berruti A.
        • Grisanti S.
        • Pulzer A.
        • et al.
        Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma.
        J Clin Endocrinol Metab. 2017; 102: 1358-1365
        • Sabolch A.
        • Else T.
        • Griffith K.A.
        • et al.
        Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
        Inter J Radiat Oncol Biol Phys. 2015; 92: 252-259
        • Fassnacht M.
        • Terzolo M.
        • Allolio B.
        • et al.
        Combination chemotherapy in advanced adrenocortical carcinoma.
        N Engl J Med. 2012; 366: 2189-2197